ISRCTN02365168已完成2 期
A phase II, open-label, single-arm study to assess the efficacy and safety of Decapeptyl® SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection
niversity Hospitals Bristol NHS Foundation Trust (UK)0 个研究点目标入组 50 人开始时间: 2010年5月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Patients must fulfil all of the following criteria in order to be included in the study:
- •1. The patient has given written (personally signed and dated) informed consent before starting any study-related procedure, which means any assessment or evaluation that would not have formed part of their normal medical care
- •2. The patient is male and is 18 years of age or older
- •3. The patient has a histologically or cytologically confirmed diagnosis of prostate cancer and meets the following criteria:
- •3.1. Stage T3 or T4, N (any), M (any) with a prostate specific antigen (PSA) greater than 5 ng/ml, or
- •3.2. Biochemical relapse following radical prostatectomy or radical radiotherapy for prostate cancer
- •4. Medical castration by means of luteinising hormone releasing hormone agonist (LHRHa) therapy is indicated for the patient
- •5. The patient has a life expectancy of at least 12 months
- •6. The patient is able and willing to comply with the requirements of the protocol
排除标准
- •Patients who fulfil any of the following criteria, will not be included in the study:
- •1. The patient has undergone bilateral orchidectomy
- •2. The patient is either scheduled to receive, receiving, or is anticipated to require any chemotherapy for prostate cancer, or any other cancer, during the period of his participation in the study
- •3. The patient is either scheduled to receive, or anticipated to require any surgical intervention for their prostate cancer during the period of his study participation
- •4. The patient has any condition that in the opinion of the Investigator may preclude the administration of subcutaneous Decapeptyl® SR injections
- •5. The patient has received treatment with any LHRHa within 1 year prior to study entry
- •6. The patient has a history of hypersensitivity to Decapeptyl® SR or CPA or to any of the excipients of Decapeptyl® SR or CPA
- •7. The patient has any contraindication to treatment with anti-androgens, including, but not limited to clinically significant abnormalities in liver function
- •8. The patient has been treated with oestrogens or steroid androgens within the 12 months prior to screening, or is receiving treatment with non-steroid anti-androgens at the time of the screening visit
- •9. The patient, in the opinion of the Investigator is at risk of serious complications in the event of tumour flare (e.g., vertebral metastases threatening spinal cord compression, significant obstructive uropathy) on initiation of Decapeptyl® SR treatment, despite concomitant treatment with anti-androgens
- •10. The patient has any other condition that, in the opinion of the Investigator, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study
- •11. The patient is likely to require treatment during the study with drugs that are not permitted by the study protocol
- •12. The patient has received any investigational drug, within 30 days prior to the study or is scheduled to receive such a drug during the study
- •13. The patient has a history of, or known current, problems with alcohol abuse
- •14. The patient has any mental condition rendering him unable to understand the nature, scope and possible consequences of the study
- •15. The patient has previously been enrolled in this study
研究者
相似试验
已完成
2 期
A phase II, open label, single arm study to assess the efficacy of AZD9291 in patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy(WJOG8815L)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000022076Clinical trial coordinating committee for WJOG8815L investigator-initiated multicenter clinical trial60
撤回
2 期
A Phase 2, Open-label, Single-arm Study to Evaluate the Tolerability, Safety, and Pharmacodynamic Effects of KER-012 in Participants with Chronic Heart Failure.Cardiovascular - Other cardiovascular diseasesChronic Heart FailureACTRN12623001290684Keros Therapeutics, Inc.12
进行中（未招募）
1 期
A study to assess the effectiveness of the drug lucitanib in lung cancer patientsFGFR1-amplified squamous non-small cell lung cancer (NSCLC)MedDRA version: 16.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003874-29-ITEOS S.p.A.40
进行中（未招募）
1 期
A study to assess the effectiveness of the drug lucitanib in lung cancer patientsEUCTR2013-003874-29-ESEOS S.p.A.18
进行中（未招募）
1 期
_Patients with progressing metastatic breast cancer pretreated with at least one line of chemotherapy at the metastatic setting.MedDRA version: 18.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2015-000580-14-FRICANCER40